Lower uric acid levels may be better in chronic kidney disease
KEY POINT
Use of febuxostat (Uloric—Takeda) 40 mg once daily for 6 months in patients with asymptomatic hyperuricemia and stage 3 or 4 chronic kidney disease (CKD) slowed the decline in estimated glomerular filtration rate (eGFR) compared with placebo, according to results of a small, single-center study published in the American Journal of Kidney Diseases.
SOURCES
Sircar D et al. Efficacy of febuxostat for slowing the GFR decline in patients with CKD and asymptomatic hyperuricemia: a 6-month, double-blind, randomized, placebo-controlled trial. Am J Kidney Dis. 2015;945–50.
Levy G et al. Is it time to start treating asymptomatic hyperuricemia [editorial]? Am J Kidney Dis. 2015;933–5.
Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Inter. 2013 (Suppl);3:1–150.
